Skip to main navigation Skip to search Skip to main content

Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study

  • Giorgio V. Scagliotti
  • , Keunchil Park
  • , Shekar Patil
  • , Janusz Rolski
  • , Tuncay Goksel
  • , Renato Martins
  • , Steven J.M. Gans
  • , Carla Visseren-Grul
  • , Patrick Peterson
  • University of Turin
  • Bangalore Institute of Oncology
  • Maria Sklodowska-Curie Institute of Oncology
  • Ege University
  • University of Washington
  • St Jansdal Hospital
  • Eli Lilly Netherlands
  • Eli Lilly

Research output: Contribution to journal › Article › peer-review

47   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry